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Perifosine is a promising anticancer alkylphospholipid (ALP) that induces apoptosis in tumor cells. Here we report evidences against a role of
endocytosis in perifosine uptake by human KB carcinoma cells. We have generated a KB cell line resistant to perifosine (KB PERR clone10),
which shows cross-resistance to the ALPs miltefosine and edelfosine, a marked impairment in the uptake of 14C-perifosine at both 37 °C and 4 °C,
and no signs for active efflux of the drug. KB PERR clone10 cells show a similar rate of raft-dependent endocytosis with respect to the parental
cells, and silencing of both clathrin and dynamin in the latter causes only minor changes in the rate of perifosine uptake. Perifosine uptake is a
temperature- and ATP-dependent, N-ethylmaleimide- and orthovanadate-sensitive process in parental cells. Accumulation of 14C-perifosine and
the fluorescent phospholipid analogue 6-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl)aminocaproyl]-phosphatidylethanolamine (NBD-PE) is inhibited by
perifosine in a concentration-dependent manner in parental cells. Moreover, NBD-PE accumulation is slower in PERR clone10 cells and correlated
with phosphatidylserine exposure in their plasma membrane surface. Together, all these data suggest a role of plasma membrane translocation by a
putative phospholipid translocase, rather than endocytosis, as the true mechanism for ALPs uptake in KB carcinoma cells.
© 2007 Elsevier B.V. All rights reserved.Keywords: Alkylphospholipids; Perifosine uptake; Tumor cells; Endocytosis; Aminophospholipid translocase1. Introduction
The synthetic antineoplastic 1-O-octadecyl-2-O-methyl-rac-
glycero-3-phosphocholine (ET-18-OCH3, edelfosine), and hex-
adecylphosphocholine (HePC, miltefosine), constitute a class of
anticancer drugs that act at the level of cell membranes and,
therefore, their effects are independent of the proliferative state
of target cells [1,2]. Edelfosine has become the prototype of the
synthetic ALPs, and selectively induces apoptosis in both
human tumor cell lines and primary tumor cell cultures from
cancer patients [3]. Its mechanism of apoptosis induction con-
sists of interfering with phospholipid turnover [4,5], causing⁎ Corresponding authors. Tel.: +34 958 181667; fax: +34 958 181632.
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0005-2736/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2007.10.017persistent activation of c-Jun amino-terminal kinase pathway
(JNK) [6] and mitochondrial-related events [7,8], and the
activation of the death receptor Fas/CD95 independently of its
ligand FasL, through its co-clustering with membrane rafts
[9,10].
Perifosine (octadecyl-[N,N-dimethyl-piperidinio-4-yl]-phos-
phate) is an oral bioactive novel ALP, structurally related to
miltefosine but with an improved tolerability profile, that has been
reported to promote apoptosis in a similar manner like edelfosine:
by recruiting death receptors and downstream signalling
molecules into lipid rafts [11]. Perifosine displays a strong
antineoplastic effect in human tumor cell lines [12] and is
currently being tested in phase II clinical trials for treatment of
major human cancers. However, the action of the ALPs is very
specific and dependent on the malignant state of the tumor cells,
existing a clear correlation between cellular uptake and ALP-
induced apoptosis [3]. Therefore, uptake ofALPs by tumor cells is
a prerequisite for triggering the intracellular events that in the last
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concentration must be reached in order to induce apoptosis [9].
Previous reports suggest that ALPs are internalized via raft-
mediated endocytosis in both mouse lymphoma [13] and human
carcinoma [14] cells. However, this mechanism of internaliza-
tion cannot be universal, since other works have ruled out
endocytosis to play a role in ALP uptake in other mammalian
cell lines [15–17]. Instead, they have postulated the existence of
a “cellular structure”, putatively absent or present in low basal
amounts in normal cells but synthesized in higher amounts in
tumor cells, as responsible for the ALP uptake and the sub-
sequent ALP-induced apoptosis [3]. In fact, Zoeller et al. [17]
have generated cell mutants derived from the edelfosine-
sensitive murine RAW 264.7 cells that showed a marked im-
pairment in their ability to accumulate edelfosine and both
choline and ethanolamine phospholipids, with normal rates of
endocytosis. This suggests that the postulated “cellular struc-
ture” responsible for ALP uptake could be a putative phos-
pholipid translocase in the plasma membrane, at least in some
tumor types.
In the present work we provide evidences that strongly
support membrane translocation by an ATP-dependent, N-
ethylmaleimide- and vanadate-sensitive phospholipid translo-
case as the most plausible mechanism for ALPs uptake in
human KB epidermal carcinoma cells, and reject a main role of
endocytosis in the uptake of ALPs in these tumor cells.
2. Materials and methods
2.1. Chemicals
Miltefosine (hexadecylphosphocholine), perifosine (octadecyl-[N,N-
dimethyl-piperidinio-4-yl]-phosphate), and [14C]-perifosine (30.9 mCi/
mmol) were provided by Zentaris GmbH (Frankfurt, Germany). Edelfosine
(1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine), anti-clathrin and
anti-dynamin antibodies were from Calbiochem. BODIPY-lactosylceramide,
Alexa Fluor 488-Annexin V, Alexa Fluor 488-transferrin and Alexa Fluor 488-
labeled Dextran 10,000 were from Invitrogen. Pre-designed ON-TARGETplus
siRNA for human dynamin mRNA was from Dharmacon. (7-nitro-2-1,3-
benzoxadiazol-4-yl)-labeled phospholipids (NBD-phospholipids) were from
Avanti Polar Lipids. GF120918 was kindly provided by GlaxoSmithKline. All
other chemicals were from Sigma-Aldrich.
2.2. Cell cultures
The human epidermal carcinoma KB cell line was obtained from the
American Type of Cell Cultures (ATCC number CCL-17), and cultured in
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (v/v)
fetal bovine serum (FBS), 2 mM Glutamax I, and 250 U/ml penicillin G plus
250 μg/ml streptomycin sulphate (Invitrogen), at 37 °C in a humidified
atmosphere and 5% CO2. In order to generate a perifosine-resistant cell line,
parental KB cells were subjected to mutagenesis with ethyl-methanesulphonate
(1 mg/ml) for 4 h, and then extensively washed and grown in fresh medium for
48 h. After that, they were subjected to several selective rounds of incubation
with high concentrations of perifosine (IC90) for short intervals (2–3 h), and the
surviving cells of each round were allowed to expand before a new incubation in
the presence of the drug. After this selection process, the resulting survival
population was able to grow in the presence of 20 μM perifosine indefinitely,
and the resistant phenotype was stable for more than 1 month growing without
drug pressure. Afterwards, this resistant population was plated at low density
and single colonies were isolated, expanded, and its inability to accumulate 14C-
perifosine analyzed. In this way, we were able to isolate several resistant clones,being the clone10 (KB PERR clone10) the one that showed the lowest levels of
perifosine accumulation of all the tested clones. Considering the stability of the
resistant phenotype, it was unnecessary to maintain the PERR clone10 in the
continuous presence of perifosine: instead, we routinely grew them for 1–2
passages with 20 μM perifosine every month.
2.3. MTT survival assays
Sensitivity of parental KB (Wt) and KB PERR clone10 cells to ALPs was
determined by the MTT colorimetric assay as described [18]. Briefly, cells were
plated in 96-well plates at a density of 1×104 cells (100 μl/well), allowed to
attach overnight, and ALPs were added in serial dilutions. After 24 h, cells were
incubated with 0.5 mg/ml MTT solution for 4 h, and the resulting formazan
crystals dissolved by adding 50 μl 10% SDS overnight. Absorbance was
measured at 540 nm with a VERSAmax microplate reader (Molecular Devices).
Dose–response curves were generated by plotting percentage of cell survival
against concentration of ALPs, and the data points (mean±S.D.; Pb0.05, n=3)
were fitted by non-linear regression to a four parameter logistic curve using
SigmaPlot 2000 for Windows (SPSS Inc.) to determine IC50 values.
2.4. 14C-perifosine uptake
Cells were plated in 24-well plates (2.5×104 cells/well), and incubated
overnight. Afterwards, cells were pre-treated for 30 min with different drugs and
inhibitors dissolved in DMEM+10% FBS, except indicated otherwise: 10 μM
NBD-PE, 2 mM N-ethylmaleimide (NEM), 5 mM sodium orthovanadate, ATP-
depleting medium [HPMI buffer (100 mM NaCl, 5.4 mM KCl, 0.04 mM CaCl2,
10 mM Hepes, 25 mM NaHCO3) with 20 mM 2-deoxy-D-glucose and 10 mM
sodium azide], 10 μM cyclosporine A, 3 μM GF120918, increasing concen-
trations of methyl-β-cyclodextrin (MβCD) up to 10 mg/ml in DMEM without
FBS, or chlorpromazine, perifosine, edelfosine and miltefosine up to 20 μM (at
both 37°C and 4 °C), where indicated. Hereafter, cells were incubated with 14C-
perifosine (0.03 μCi/ml, 1 μM) at either 37 °C or 4 °C for 1–2 h or 20–50 min,
respectively, depending on the experiment, and subjected to back-exchange
using 2% fatty acid-free BSA in HPMI for 5 min at 4 °C, in order to remove the
excess of perifosine in the external face of the plasma membrane. In the case of
samples pre-treated with MβCD, the cells were thoroughly washed before
adding 14C-perifosine in order to completely remove MβCD, since we observed
that the cholesterol-depleting agent also sequestered perifosine and hence
lowered the concentration of free 14C-perifosine. We also checked under the
microscope the cells immediately after chlorpromazine or MβCD pre-treatment,
and they look healthy, with no observable changes in cell morphology or
membrane integrity. We observed, however, some cell detachment when
incubated with the highest concentration of MβCD employed (10 mg/ml);
however, the cell loss was took into account when calculating the accumulation
of 14C-perifosine (always normalized to protein content), it was never higher
than 20% of total cell number, and the remaining, attached cells (those that really
accumulated 14C-perifosine) looked perfectly normal. For efflux experiments,
KB Wt and PERR clone10 cells were incubated with 14C-perifosine for 15 min
or 5 h, respectively, in order to achieve similar intracellular concentrations of the
drug in both cell lines at time zero of efflux. After this loading period, the cells
were washed and incubated in fresh, drug-free culture medium, allowing them to
extrude the radioactive drug analogue. At appropriate time points, cells were
washed once with ice-cold HPMI buffer, followed by back-exchange with 2%
fatty acid-free BSA in HPMI for 5 min at 4 °C, washed once more with HPMI
buffer, and subsequently lysed in 1% Triton X-100 plus 0.25 N NaOH. The
cellular lysated was further diluted in liquid scintillation cocktail (EcoLume™,
MP Biomedicals) for counting in a LKB/WALLAC 1219 Rack-Beta Scintilla-
tion Counter. The radioactivity values obtained, expressed in counts per minute
(cpm), was normalized for the protein content of the samples.
2.5. Accumulation of fluorescent phospholipid analogues
Cells previously seeded in 24-well plates the day before, were incubated for
either 15 min at 37 °C or 40 min at 4 °C with 2 μM NBD-phosphatidyletha-
nolamine, -phosphatidylserine or -phosphatidylcholine (NBD-PE, -PS, -PC)
diluted in DMEM+10% FBS. For competition assays, we used 0.2 μM NBD-
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Chlorpromazine (up to 20 μM) or MβCD (up to 10 mg/ml) was used as inhibitor
of NBD-PE uptake. After the incubation times, the plates were placed on ice and
all subsequent steps were performed at 4 °C: washed once with HPMI buffer,
back-exchanged with 2% fatty acid-free BSA in HPMI for 5 min at 4 °C, washed
once more with phosphate-buffer saline (PBS), trypsinized for 1 min and
resuspended in PBS+5 mM EDTA. The fluorescence of the samples was
immediately measured by using FACSCalibur cytometer (BD Biosciences), and
the data were analyzed using the BD CellQuest™ Pro software.
2.6. Alexa Fluor 488-Annexin V labeling of KB Wt and KB PERR
clone10 cells
We used an adaptation of the protocol described previously in [19] for
labeling adherent cells with Annexin V. Briefly, we labeled cell cultures in
exponential growth before harvesting, with 1 μg/ml Alexa Fluor 488-Annexin V
in DMEM medium without FBS for 1 h at 4 °C. We did so in order to avoid the
overestimation of phosphatidylserine exposure due to damages caused to cell
membranes during the harvesting process. Then, cells were rinsed twice with
ice-cold DMEM and resuspended in 0.5 ml DMEM by gently aspirating with a
pipette. Finally, propidium iodide (1 μg/ml final concentration) was added and
the cells kept on ice 5 min before immediate analysis by flow cytometry. PI-
positive cells were excluded from the analysis.
2.7. Measurement of endocytosis rates
Cells plated in 24-well plates the day before were incubated with Alexa-488
fluorescently labeled human transferrin (25 μg/ml) in serum-free medium,
BODIPY-lactosylceramide (0.5 μM) or with the fluorescent fluid-phase marker
Alexa Fluor 488-Dextran 10,000 (0.25 mg/ml) in complete medium for 7 min at
37 °C. The cells to be labeled with the fluorescent endocytic markers transferrinFig. 1. Sensitivity of KB Wt and KB PERR clone10 cells to several cytotoxic drugs:
depicted representative experiments of three different experiments performed in tripor BODIPY-lactosylceramide were previously treated as follows: the former was
serum-starved for 30 min at 37 °C before adding the fluorescently labeled
transferrin; the latter was incubated 15 min with BODIPY-lactosylceramide at
4 °C, to allow the partitioning of the fluorescent marker into the cholesterol-
enriched micro-domains of the plasma membrane, then thoroughly washed with
ice-cold PBS to remove the excess of fluorophore, and warmed up to 37 °C for
7 min. Endocytosis was stopped on ice. Cells were washed thoroughly with cold
PBS to remove the excess of untaken fluorescence, back-exchanged twice with
2% defatted BSA at 4 °C 10 min each in the case of the cells labeled with
BODIPY-lactosylceramide, or acid-stripped 30 s at 10 °C with HPMI, pH 3.5 in
the case of those labeled with Alexa Fluor 488-transferrin to remove the
receptor-bound transferrin analogue [20]. Then, cells were trypsinized and
resuspended in cold PBS+0.5 mM EDTA. The samples were immediately
analyzed by flow cytometry using a FACSCalibur cytometer (BD Biosciences),
and the data were analyzed using the BD CellQuest™ Pro software.
2.8. siRNA-based dynamin knockdown
Human dynamin 1, a key protein in both clathrin- and raft-dependent
endocytosis, was targeted using SMARTpool siRNA oligonucleotides (Dhar-
macon). siRNA oligonucleotides (100 nM) were transfected into cells seeded the
day before on 24-well plates (30–50% confluent) with 1:500 Dharmafect I
(Dharmacon) in Opti-MEM reduced-serum medium (Invitrogen) for 5 h. Then,
the transfection mixture was replaced by fresh DMEM+10% FBS, and the cells
were further cultured for 48 h before the experiments were performed.
2.9. Western blotting
After 48 h of siRNA treatment, cells were washed twice with cold PBS,
lysed by the addition of lysis buffer (5 M urea, 1% SDS, 10 mM Tris pH 6.8,
0.1 mM EDTA, 1% β-mercapto-ethanol, plus 1:50 cocktail of proteaseA) perifosine; B) miltefosine; C) edelfosine; D) daunorubicin. There have been
licate for each drug concentration.
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0.1% Triton X-100 and incubated at −20 °C for 15 min. The samples (25 μg
protein per lane) were resolved by 10% SDS-PAGE and transferred to PVDF
membranes. Membranes were subsequently blocked for 1 h at room temperature
in 5% defatted milk in PBS 0.05% Tween 20 (PBS-T), and washed three times
with PBS-T. Immunodetection was performed by incubating the blocked
membranes with monoclonal primary antibodies at room temperature for 1 h,
followed by several washes and subsequent incubation with horseradish
peroxidase-conjugated anti-mouse IgG (Promega). Immunoreactive proteins
were visualized using a chemiluminescence detection kit (Pierce ECL Western
Blotting Substrate) according to the manufacturer's instructions. To strip and
reprobe, the membranes were incubated in Restore Western Blot Stripping
Buffer (Pierce) at 37 °C for 15 min, washed, blocked, and immunoblotted with
monoclonal anti-α-tubulin antibodies (Sigma) as protein loading control.
3. Results
3.1. KB PERR clone10 cells are cross-resistant to several
ALPs, but not to classical DNA-targeting anti-cancer drugs
We have generated a cell clone highly resistant to perifosine
(KB PERR clone10) from the parental human KB (Wt) cells by
mutagenesis and several rounds of selection at increasing con-
centrations of perifosine. We performed MTT-based colorimetric
survival assays and found that the PERR clone10 displayed a high
resistance to perifosine (IC50=35.8±3.5 μM)with respect to KB
Wt cells (IC50b0.1 μM) (Fig. 1A).Moreover, KB PERR clone10
cells showed also cross-resistance to miltefosine (Fig. 1B) and
edelfosine (Fig. 1C) compared with KB Wt cells (for PERRFig. 2. Uptake of 14C-perifosine (0.03 μCi/ml, 1 μM) in KB Wt and KB PERR clone1
the ABC transporter inhibitors cyclosporine A (CsA) or GF120918 (C). In (D) is s
clone10 cells at 37 °C. Representative experiments of 2–3 different experiments peclone10 and Wt cells, respectively: miltefosine IC50s=66.7±7.8
vs. 0.1±0.02 μM; edelfosine IC50s=18.1±3.4 vs.b0.1 μM).
On the other hand, we wanted to test if KB PERR clone10
cells were also resistant to other classical anti-cancer drugs like
the anthracycline daunorubicin, and found that KB Wt and
PERR clone10 cells were equally sensitive to this drug
(Fig. 1D). All these findings suggest that: first, whatever the
mechanism of perifosine resistance in KB PERR clone10 cells,
it should be common for all ALPs tested; second, this
mechanism does not account for resistance to classical anti-
cancer drugs; and third, at least those elements shared by both
daunorubicin- and ALPs-triggered cell death pathways (Bid,
Bax, Bcl-2, cytochrome c release, and activation of the effector
caspase-8 and caspase-3) [8,21] should also be functional in KB
PERR clone10 cells as well as in Wt cells. Therefore, abrogation
of cell death pathways cannot account for the ALPs-resistance
phenotype observed in these cells.
3.2. KB PERR clone10 cells accumulate much lower levels of
14C-perifosine than parental cells due to a defect in perifosine
internalization
We performed 14C-perifosine accumulation experiments in
KB Wt and PERR clone10 cells, in order to investigate their
respective abilities to internalize the drug, and found that the rate
of radiolabelled drug uptake at 37 °Cwasmuch slower in clone 10
than in Wt cells (Fig. 2A). To establish whether the observed0 cells at 37 °C (A,C), at 4 °C (B), and after ATP depletion or in the presence of
howed the comparison of 14C-perifosine efflux between KB Wt and KB PERR
rformed in duplicate are showed.
Fig. 3. Inhibition of 14C-perifosine uptake by increasing concentrations of cold
perifosine,miltefosine and edelfosine inKBWt cells at both 4 °C (A) and 37 °C (B).
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cytosis or membrane translocation, we performed the same
experiment but at 4 °C, where no endocytosis occur (Fig. 2B).We
observed that 14C-perifosine in Wt cells equilibrated between the
two leaflets of the plasma membrane within 30–40 min, with a
half-maximal accumulation time (t1/2) of around 7 min. However,
drug equilibration in the plasmamembrane of PERR clone10 cells
took a longer time (around 60 min.), with t1/2≈15 min. This
implies that the perifosine internalization impairment observed in
PERR clone10 cells was, at least in part, due to a lower rate of
translocation through the plasma membrane.
Finally, we wanted to check whether the lower levels of
perifosine accumulation observed in PERR clone10 cells were or
were not due to an active mechanism of drug extrusion (e.g.
over-expression of ABC pumps) absent or present at lower
levels in KB Wt cells. We performed experiments of perifosine
uptake either after ATP depletion, or in the presence of the ABC
transporter inhibitors cyclosporine A and GF120918 (Fig. 2C).
Depletion of ATP dramatically inhibited the uptake of perifosine
in KB Wt cells at 37 °C, suggesting that such uptake is highly
dependent on the cellular ATP levels. On the other hand, uptake
of perifosine in KB PERR was unaffected by ATP depletion,
which suggests that no active internalization of perifosine takes
place in this cell line (no ATP-dependent translocase). If an
active efflux pump for perifosine existed in PERR cells, the ATP
depletion should have raised the uptake of perifosine up to the
levels measured inWt cells in the same experimental conditions;
however, this was not observed. The pre-treatment with either
cyclosporine A or GF120918, which are inhibitors of three
classic efflux pumps that belong to the ABC superfamily of
transporters (MDR1/MRP1, and ABCG2/MDR1, respectively),
had no effect in the rate of perifosine uptake in KB PERR cells,
which suggest that none of these efflux pumps contribute to the
perifosine-resistance phenotype observed in PERR cells. It is
worth noting that cyclosporine A partially inhibited the uptake of
perifosine inWt cells, which could imply that this drug would be
able to inhibit the aminophospholipid translocase(s). This obser-
vation would explain the reported pro-coagulant effect of cyclo-
sporine A by inducing the exposition of PS in platelets [22].
Both cell lines were loaded with 14C-perifosine, and then
allowed to extrude the drug in order to measure possible dif-
ferences in their respective drug efflux rates. We observed no
differences at all in the drug efflux rates between both cell lines
(Fig. 2D), which made us to conclude that the lower
intracellular accumulation of perifosine in PERR clone10 with
respect to Wt cells was due to a slower rate of drug inter-
nalization, rather than an increased drug efflux.
3.3. ALPs compete with the uptake of 14C-perifosine in a
concentration-dependent manner
Considering that perifosine seemed to enter in KB cells by
translocation through the plasma membrane, we wanted to
determine if such translocation process was saturable at in-
creasing concentrations of the drug, which would exclude
passive diffusion as well as endocytosis as major mechanisms
responsible for perifosine uptake. Instead, saturation wouldimply the involvement of a putative membrane transporter or
receptor. We found that the rate of 14C-perifosine accumulation
in KB Wt cells in the presence of 10% FBS (or BSA 0.3%) was
linear up to 10–15 μM perifosine, but at higher concentrations
the rate started to slow down until complete saturation at 70–
80 μM perifosine (not shown). The 14C-perifosine uptake
process could be described by a hyperbola with Km≈18 μM.
Interestingly, when 14C-perifosine was added to the cells in a
medium without FBS (FBS-free medium only at the moment of
the experiment), we observed that the drug accumulation did not
saturate, but was linearly dependent on 14C-perifosine con-
centration up to at least 160 μM, and it proceed faster than in the
presence of 10% FBS (not shown). Strikingly, in the absence of
FBS we observed that PERR clone10 cells showed a similar
sensitivity to perifosine than parental cells, and they also took
up similar amounts of 14C-perifosine. These findings suggest
that perifosine molecules should be complexed with the BSA
present in FBS for their proper insertion in the plasma mem-
brane because, in the absence of FBS, perifosine seems to be
internalized by a non-saturable process, as previously described
for other alkylphospholipids like edelfosine [23].
However, since ALPs can act as detergents and produce
membrane fluidification [24] and cell lysis [25] at high concen-
trations, the observed “saturation” of 14C-perifosine accumula-
tion could be due to non-specific perturbations of the plasma
membrane at the higher concentrations of 14C-perifosine used
above. Thus, in order to rule out this non-specific effect of
ALPs, we performed competition assays of 14C-perifosine in
the presence of cold perifosine, miltefosine and edelfosine at
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the three ALPs reduced the uptake of 14C-perifosine by 20 to
45% in a concentration-dependent manner. The EC50s (con-
centration that causes the half-maximal effect observed) were
3.26±0.47 μM, 2.36±0.01 μM and 1.82±0.13 μM for
perifosine, miltefosine and edelfosine, respectively. Whatever
the mechanism inhibited by ALPs at 4 °C, it was also relevant at
37 °C, as shown in Fig. 3B.
3.4.14C-perifosine uptake is related to aminophospholipid
translocation in human KB cells
Taking into account the structural similarities between ALPs
and natural phospholipids at molecular level, and the resultsFig. 4. Accumulation of NBD-phospholipid analogues in KB Wt and KB PERR clon
37 °C (A); uptake of NBD-PE at 37 °C (B) and 4 °C (C); endogenous phosphatidylser
inhibition of NBD-PE uptake at 4 °C by increasing concentrations of perifosine. A rep
(B), (C) and (D), the respective controls are depicted in dotted lines.exposed above, we considered that P4-type aminophospholipid
translocases [26] could be good candidates for putative
mediators of ALPs uptake in human KB cells. To test our
hypothesis we performed experiments of accumulation of the
fluorescent phospholipid analogues NBD-PE, -PS and -PC,
monitored by flow cytometry, using both KB Wt and PERR
clone10 cells. The best correlation between perifosine and
NBD-phospholipid uptake was found with NBD-PE, rather than
with NBD-PS or -PC, as shown in Fig. 4A. We found that PERR
clone10 cells accumulated 10- and 2-fold less NBD-PE than Wt
cells at 37 °C (Fig. 4B) and 4 °C (Fig. 4C), respectively, after
20 min incubation, which is in agreement with their respective
abilities to translocate perifosine at both 37 °C (Fig. 2A) and
4°C in the linear range (the first 10 min; Fig. 2B) of uptakee10 cells: uptake of perifosine compared with that of NBD-PE, -PS and -PC at
ine exposure revealed by Alexa 488-Annexin V binding (D). In (E) is showed the
resentative experiment of two different ones performed in duplicate is shown. In
Fig. 5. Uptake of 14C-perifosine at 4 °C in KB Wt is in part dependent on ATP,
and sensitive to the P-type aminophospholipid translocases inhibitors NEM and
vanadate. Uptake in KB PERR clone10 cells is lower than in Wt cells, and it is
neither an active process (ATP-independent) nor sensitive to NEM and vanadate.
Fig. 6. Effects of chlorpromazine (A) and MβCD (B) in the uptake of 14C-
perifosine (at both 37 °C and 4 °C), and in the endocytosis of transferrin and
lactosyl-ceramide (LacCer), which are the respective controls of clathrin- and
raft-dependent endocytosis.
536 F. Muñoz-Martínez et al. / Biochimica et Biophysica Acta 1778 (2008) 530–540through the plasma membrane. We also observed that Alexa
Fluor 488-Annexin V binding to the cell surface was higher in
PERR clone10 cells (Fig. 4D), which implied that these cells
exposed more phosphatidylserine than parental KB cells, and
that phospholipid asymmetry of these cells should be at least
partially disrupted, which suggests a lower aminophospholipid
translocase activity in PERR cells.
Finally, we found that perifosine inhibited in KBWt cells the
internalization of NBD-PE at 4 °C (Fig. 4E) in a concentration-
dependent manner up to 10 μM (a concentration low enough as
to discard the possibility of membrane-perturbing effects). In a
reciprocal way, we found that 10 μM NBD-PE inhibited the
uptake of perifosine by about 50%, which, along with the above
result, strongly suggest that both perifosine and NBD-PE could
be competing for the same transporter to enter KB Wt cells.
3.5. KB Wt displayed an ATP-dependent, NEM- and
vanadate-sensitive perifosine-translocase activity absent
in PERR clone10 cells
Given that perifosine uptake in KB cells seemed to be
mediated by a membrane aminophospholipid translocase,
and that the family of proteins such translocases belong to are
NEM- and vanadate-sensitive ATPases [26], we performed 14C-
perifosine accumulation experiments at 4 °C (no endocytosis) in
both KB Wt and PERR clone10 cells in ATP-depleted
conditions, and in the absence/presence of NEM and orthova-
nadate. The results of these experiments are depicted in Fig. 5.
We found that, after 10 min incubation in control conditions
with 1 μM 14C-perifosine, PERR clone10 cells accumulated
only half the amount of perifosine than Wt cells. However, after
ATP-depletion or preincubation with either NEM or orthova-
nadate, the 14C-perifosine uptake in Wt cells decreased to the
levels of PERR clone10 cells. The uptake of 14C-perifosine by
PERR clone10 was unaffected by either ATP-depletion or
preincubation with the above-mentioned inhibitors. This dem-
onstrates that in KB Wt cells there is a perifosine-translocase
activity driven by ATP, and sensitive to the P-type ATPases
inhibitors orthovanadate and NEM. The basal amount of 14C-perifosine accumulated in PERR clone10 cells at 4 °C seemed to
be due to a slower process, driven by the concentration gradient
(either passive of protein-facilitated diffusion through the
plasma membrane).
3.6. MβCD and chlorpromazine inhibit the uptake of
14C-perifosine in KB Wt cells independently of their role
as classical endocytosis inhibitors
Despite that all the evidences gathered to this point of our
research claimed for a major role of active membrane trans-
location in the uptake of ALPs in human KB cells, we also
wanted to explore the role of endocytosis in this phenomenon.
For such purpose, we performed accumulations of 14C-
perifosine after treatment of KB Wt cells with either the
cholesterol-depleting agent MβCD (classical inhibitor of raft-
dependent endocytosis) or chlorpromazine (classical inhibitor
of clathrin-dependent endocytosis).
We found that 10–15 μM chlorpromazine inhibited the 14C-
perifosine uptake by 60% at both 37 °C and 4 °C, which is a
concentration below the IC50 for inhibition of Alexa Fluor 488-
transferrin endocytosis (around 40 μM) (Fig. 6A). Moreover,
we tested that chlorpromazine also inhibited translocation of
NBD-PE by the same extent at the same concentration range
(around 10 μM; not shown). From Fig. 6A it is clear that around
40% of 14C-perifosine uptake remained insensitive to chlor-
promazine, but higher concentrations (up to 100 μM) were able
Fig. 7. A) Uptake rates of different endocytic markers compared between KBWt
and KB PERR clone10 cells. B) Effect of clathrin and dynamin silencing in the
uptake of 14C-perifosine, NBD-PE and several endocytic markers. C) Expression
levels of clathrin heavy chain and dynamin, determined by Western blot, in
control cells (incubated with Dharmafect, lane 1) and siRNA-transfected cells
(lane 2).
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gests that clathrin-mediated endocytosis played no role in
perifosine uptake in KB cells.
On the other hand, MβCD inhibited completely the raft-
dependent endocytosis of BODIPY-lactosylceramide at 10 mg/
ml (Fig. 6B). However, around 40% of 14C-perifosine uptake at
37°C remained insensitive to MβCD-induced cholesterol
depletion. This could imply that perifosine uptake and raft-
dependent endocytosis were not linked in KB cells, or that 60%
of the perifosine uptake took place by raft-dependent endocy-
tosis and the remaining 40% was dependent on other mech-
anism, like active translocation through the plasma membrane.
However, perifosine uptake at 4 °C (where no endocytosis
occurred) showed the same profile of inhibition by MβCD than
at 37 °C. Moreover, we observed also that NBD-PE transloca-
tion through the plasma membrane was also sensitive to MβCD,
and in the same way as perifosine uptake (half-maximal
inhibition at 2–3 mg/ml MβCD, and 40% of uptake remained
insensitive to the drug). This suggests that aminophospholipid
translocase is partially dependent on the cholesterol-content of
the plasma membrane. Moreover, in a different way as de-
scribed for other cell lines [13,14], raft-dependent endocytosis
seems not to play a major role in perifosine uptake in KB cells.
3.7. KB Wt and PERR clone10 cells displayed similar rates of
endocytosis, and knock-down of clathrin and dynamin 1 did not
affect perifosine uptake
Raft-dependent endocytosis has been reported to be the
mechanism of ALPs uptake in other cell lines [13,14]. However,
we found that both Wt and PERR clone10 cells displayed
similar rates of fluid-phase and raft-dependent endocytosis
(Fig. 7A). Thus, the lower levels of perifosine uptake in clone10
cells cannot be ascribed to either of both endocytic processes.
However, we found that the rate of clathrin-dependent
endocytosis was slower in PERR clone10 cells than in their
parental counterparts (Fig. 7A).
Given that, in spite of the above evidences against the role of
both clathrin- and raft-mediated endocytosis in perifosine
uptake, we wanted to establish definitely the potential con-
tribution of any of these bulk transport processes. We decided to
knock down clathrin heavy chain and dynamin 1, both key
proteins of the endocytic machinery that play a role in clathrin-
dependent [27] and clathrin-independent, raft-dependent routes
of endocytosis [28], by using the siRNA-based ON-TARGET-
plus approach developed by Dharmacon. We found that, after
48 h of transfection with 100 nM siRNA clathrin mixture, the
rates of 14C-perifosine uptake, fluid phase (monitored by Alexa
Fluor 488-Dextran 10 KDa uptake) and clathrin-dependent
(monitored by Alexa Fluor 488-transferrin uptake) endocytosis,
were reduced around 10, 60, and 50%, respectively, versus the
control with the cationic lipid mixture alone (Fig. 7B).
However, raft-dependent endocytosis (monitored by BODIPY-
lactosylceramide uptake) was unaffected by clathrin knock-
down (Fig. 7B). On the other hand, after 48 h of transfectionwith
100 nM siRNA dynamin mixture, the rates of 14C-perifosine
uptake, fluid phase, clathrin-dependent and raft-dependentendocytosis were reduced around 10, 60, 40 and 50%,
respectively. This result, along with the rest of evidence exposed
above, allowed us to reject the role of endocytosis in perifosine
uptake in KB cells.
4. Discussion
In the present work, we have reported the generation of a cell
line derived from the perifosine-hypersensitive human KB cells
(the KB PERR clone10 cells), which are highly resistant to the
ALP perifosine and cross-resistant to other ALPs like
miltefosine and edelfosine, but not to the classical anticancer
drug daunorubicin. This cell line showed a marked impairment
in perifosine uptake, but no signs for active efflux of the drug or
abrogation of apoptosis, since daunorubicin caused rapid cell
death in both parental and PERR clone10 cells with equal
potency. Therefore, the impairment in perifosine uptake in
PERR clone10 cells seems to be the major mechanism that
accounts for the observed resistance phenotype. We have ob-
served that the differential uptake of perifosine between wild-
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of either FBS or BSA in the medium. This is not the first time
that such observation has been reported: Small et al. [23] found
that edelfosine-resistant HL-60 cells accumulated similar
amounts of edelfosine than sensitive cells in the absence of
serum albumin. It has been demonstrated that alkylpho-
spholipids (ALPs), below the critical micellar concentration
(CMC), insert progressively in lipid monolayers as monomers
from the aqueous medium, but above the CMC, an irregular
insertion of ALP molecules occurs, because not only monomers
but also groups of monomers are transferred into the mono-
layers [29]. It is known that the presence of albumin in the
medium has the effect of increasing the CMC value by binding
molecules of lipids and, hence, reducing the concentration of
free monomers in the medium [30, 31]. Albumin acts as a
perifosine reservoir [31]; it binds reversibly to the cell surface
and may release the drug gradually. Therefore, the presence/
absence of BSA clearly determines the way in which perifosine
interacts with the plasma membrane of living cells. With BSA,
perifosine will insert in the outer leaflet of the plasma membrane
as monomers, but will pass through the membrane bilayer only
where the putative ATP-dependent translocase is active (in the
membrane of wild-type cells, but not in that of PERR cells).
However, without BSA, abrupt deployment of perifosine mi-
celles into the plasma membrane will occur as soon as the CMC
is reached, overcoming in PERR cells the barrier imposed by the
absence of a translocase for perifosine, which make them as
sensitive to the drug as KBWt cells. This could also explain the
observed low levels of competition between 14C-perifosine and
perifosine, miltefosine and edelfosine (never greater than around
50%), since effective competition could only take place when
the molecules of the competitor ALP are as free monomers; once
the CMC is reached, the ALP molecules tend to cluster in
micelles and a real competition between hot and cold molecules
of ALPs cannot proceed further.
We investigated whether perifosine entered KB cells by
endocytosis, as previously reported for other cell lines [13,14],
and found that both chlorpromazine (classical inhibitor of
clathrin-dependent endocytosis) and MβCD (classical inhibitor
of raft-dependent endocytosis) reduced the uptake of perifosine
considerably. In principle, a simple interpretation of these
results would make us conclude that both clathrin- and raft-
dependent endocytosis played a major role in perifosine uptake
in KB cells. However, we wanted to make certain that the
above-mentioned inhibitors were not causing effects other than
the inhibition of endocytosis. We observed that the membrane
translocation of both NBD-PE and perifosine at 4 °C was
inhibited by chlorpromazine at concentrations below the EC50
for inhibition of clathrin-dependent endocytosis, as monitored
with Alexa Fluor 488-transferrin uptake. Moreover, we found
that: first, MβCD inhibited the translocation of both NBD-PE
and perifosine at 4 °C; second, that perifosine uptake at both
4 °C and 37 °C showed a similar profile of sensitivity to MβCD;
and third, that 40% of the perifosine uptake remained insen-
sitive to MβCD even at the highest concentrations used (10 mg/
ml), but the uptake of BODIPY-lactosylceramide (marker
of raft-dependent endocytosis) was inhibited completely. Wewanted to explore the effects of higher concentrations of MβCD
(5–10 mg/ml) than those used in previous works [13,14],
because we observed that MβCD at 1 to 2.5 mg/ml was unable
to affect endocytosis of BODIPY-LacCer in KB cells (Fig. 6B),
which suggested that membrane rafts were still unaffected and
that higher concentrations of MβCD were necessary to cause
raft-disruption without affecting cell integrity. Some authors
could criticise that the high concentrations of MβCD used (5–
10 mg/ml) could be toxic for cells. We do not doubt that raft
disruption should be deleterious for living cells, but the toxic
effects should not be apparent until several hours after MβCD
treatment. Indeed, we accumulated 14C-perifosine immediately
after MβCD treatment for no longer than 1 h, and the cells
examined under the microscope looked perfectly well before
and after such interval. Moreover, 40% of the active accumula-
tion of 14C-perifosine remained insensitive to MβCD pre-
treatment, which means that the cell membrane as a physical
barrier should be intact even at the highest concentration of
MβCD used. Otherwise, the active accumulation of the drug
could not proceed. Finally, it is worth noting that 14C-perifosine
uptake at 37 °C is significantly lowered after pre-treatment with
only 2.5 mg/ml MβCD, but endocytosis of BODIPY-LacCer
was still unaffected.
All these findings suggested that chlorpromazine and MβCD
were able not only to inhibit endocytosis, but also to block
perifosine and aminophospholipid translocation through the
plasma membrane in a concentration range that did not affect
endocytosis. In addition, it seemed that perifosine uptake in KB
cells was occurring by a process other than endocytosis, which
was confirmed when we silenced dynamin and found no effect
in the uptake of perifosine. Therefore, endocytosis is not re-
sponsible for perifosine uptake in KB cells.
KB PERR clone10 cells showed no major alterations in
endocytosis with respect to parental KB cells, which supports
what was stated above. Only the endocytosis of Alexa Fluor 488-
transferrin (clathrin-dependent) seemed to be lower in PERR
clone10 cells but, since dynamin plays a key role in clathrin-
dependent endocytosis and its silencing caused no impairment in
perifosine uptake in KB cells, we could conclude that the lower
levels of clathrin-dependent endocytosis observed in PERR
clone10 cells cannot explain the lower perifosine uptake.
Moreover, we found that perifosine uptake was saturable, and
that perifosine, miltefosine, and edelfosine inhibited the uptake
of 14C-perifosine in a concentration-dependent manner. This
suggested that perifosine uptake should be mediated by a
discrete machinery (either a transporter or a receptor), and that
whatever is the protein or complex of proteins affected in PERR
clone10 cells, it should be responsible for the uptake of all ALPs
in KB cells.
Taken into account the similarities between ALPs and natural
phospholipids, we considered it plausible that whatever is the
putative transporter implicated in the uptake of ALPs in KB
cells, it could be affected in KB PERR clone10 cells. We found
that PERR clone10 cells present a reduced uptake of NBD-PE
and an increased exposure of phosphatidylserine in the surface
of the plasma membrane with respect to the parental cells.
Given that it is long since known that uptake of spin-labeled
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spholipid analogues [34,35] in mammalian cells is mediated by
an ATP-dependent membrane translocase, these findings sug-
gest that an aminophospholipid translocase activity, which con-
tributes to create the phospholipid asymmetric distribution typical
in the plasma membrane of any eukaryotic cells [26,36] was
absent or greatly lowered in PERR clone10 cells. Unsurprisingly,
we were able to establish that perifosine translocation at 4 °C in
KBcells was an active process, dependent onATP and sensitive to
NEM and orthovanadate, which are the hallmarks of the P-type
ATPases like aminophospholipid translocases [26]. Even more
interestingly, such activity was absent in PERR clone10 cells, and
perifosine inhibited the translocation of NBD-PE in a concentra-
tion-dependent manner, which suggests that both natural
aminophospholipids and ALPs compete for the same transporter
to be internalized in KB cells.
In conclusion, the results presented in this work point towards
the implication of a putative aminophospholipid translocase in
the uptake of ALPs in human KB cells, as it has also been
described previously in yeasts [37] and protozoan parasites [38].
Moreover, the present work points out, as previous works also
did [39,40], that great care should be taken when using chlor-
promazine and MβCD as endocytosis inhibitors, since these
compounds seem to have pleiotropic effects (like the inhibition
of aminophospholipid translocases observed here), and could
lead researchers to link erroneously a given phenomenon to
endocytosis.
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